CRL (Charles River Laboratories International) Other Long Term Assets: $641 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRL Charles River Laboratories International Inc CRL
74 GF Score
Price $280.05
GF Value $194.36
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Charles River Laboratories International Other Long Term Assets?

Charles River Laboratories International CRL -0.43% 74 Other Long Term Assets is $641 Mil as of Jun. 2026. GuruFocus rates CRL with a GF Score™ of 74/100 and a GF Value™ of $194.36 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Charles River Laboratories International's other long-term assets for the quarter that ended in Jun. 2026 was $641 Mil.

Charles River Laboratories International's quarterly other long-term assets increased from Dec. 2025 ($361 Mil) to Mar. 2026 ($915 Mil) but then stayed the same from Mar. 2026 ($915 Mil) to Jun. 2026 ($641 Mil).

Charles River Laboratories International's annual other long-term assets declined from Dec. 2023 ($350 Mil) to Dec. 2024 ($320 Mil) but then increased from Dec. 2024 ($320 Mil) to Dec. 2025 ($361 Mil).

Charles River Laboratories International Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Charles River Laboratories International's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Charles River Laboratories International Other Long Term Assets Chart

Charles River Laboratories International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 191.76 189.54 349.66 320.41 360.52

Charles River Laboratories International Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 343.40 327.80 360.52 914.76 641.38
CRL
74GF Score
Charles River Laboratories International Inc CRL
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Charles River Laboratories International Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of $641 Mil mean?
Charles River Laboratories International (CRL) has a Other Long Term Assets of $641 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Charles River Laboratories International and its competitors.
Is Charles River Laboratories International's Other Long Term Assets too high?
Charles River Laboratories International's current Other Long Term Assets is $641 Mil. Overall, Charles River Laboratories International has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's Other Long Term Assets compare to RVTY and ICLR?
Charles River Laboratories International's Other Long Term Assets of $641 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Medical Diagnostics & Research company?
A good Other Long Term Assets depends on the Medical Diagnostics & Research industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Charles River Laboratories International and its competitors. Charles River Laboratories International's current Other Long Term Assets is $641 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (CRL) is currently considered Significantly Overvalued. The stock's GF Value™ is $194.36, compared to a current price of $280.05 — trading 44.1% above its estimated fair value. The current Other Long Term Assets is $641 Mil. Charles River Laboratories International's overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Charles River Laboratories International (CRL), the current Other Long Term Assets is $641 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Charles River Laboratories International (CRL) Overvalued in 2026?

Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued. The current stock price of $280.05 is trading 44.1% above its estimated GF Value™ of $194.36. GuruFocus considers Charles River Laboratories International to be Significantly Overvalued.

Key valuation signals for CRL:

  • Other Long Term Assets: $641 Mil
  • GF Value™: $194.36 vs. price of $280.05 (44.1% above fair value)
  • GF Score™: 74/100 with 9 warning signs

No single metric tells the full story. See the CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Charles River Laboratories International Business Description

Other Exchanges RV6:Germany
Address 251 Ballardvale Street, Wilmington, MA, USA, 01887
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
74GF Score

Get the complete analysis for CRL

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$280.05
Price
$194.36
GF Value